个体化有限采样方法更准确估计FVIII浓缩剂终末半衰期
研究从WAPPS-Hemo数据库提取331项富采样药代动力学研究,比较个体化有限采样(Personalized LSA)与随机采样两种两样本方案对FVIII终末半衰期估计的误差。结果显示个体化LSA组相对误差中位数-第95百分位为3.8%-13.1%,显著低于随机采样组的7.0%-23.5%(P<10^-10),且个体化LSA建议的采样点中低于定量下限的比例不足4%。
要点
- 个体化LSA组终末半衰期估计相对误差中位数-第95百分位为3.8%-13.1%,随机采样组为7.0%-23.5%(P<10^-10)。
- 个体化LSA建议的采样点中低于定量下限的样本不足4%。
- 个体化LSA可提高稀疏采样下FVIII终末半衰期估计的精确度。
核心结论
- 个体化有限采样方法考虑个体间药代动力学差异,识别信息量最大的采样点,可提高稀疏采样下FVIII终末半衰期估计的精确度。
研究设计与样本
- 从WAPPS-Hemo数据库提取331项富采样药代动力学研究,构建并比较两种两样本方案:个体化LSA预测选点构建974项研究,随机选点构建974项研究。
- 在稀疏数据上估计半衰期,并与同一患者富数据估计值比较以评估半衰期误差。
主要发现
- 个体化LSA稀疏采样与富采样估计值的相对误差中位数-第95百分位为3.8%-13.1%,随机采样组为7.0%-23.5%(P<10^-10)。
- 个体化LSA建议的采样点中低于定量下限的样本不足4%。
- 个体化LSA的相对误差始终低于20%,且显著低于随机采样组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Hemophilia A is a bleeding disorder characterized by a deficiency of a coagulation factor VIII and optimally treated using pharmacokinetics (PK)-guided prophylactic replacement therapy. To decrease patient burden, PK can be estimated from sparse sampling leveraging population PK modeling. However, recommendations for sampling times meant for patients with hemophilia A as a group may not be optimal at the individual level. OBJECTIVE: To evaluate a personalized limited sampling approach (Personalized LSA) that suggests a next sampling time point that would provide a more accurate estimation of terminal half-life of FVIII concentrates when using a population PK approach. METHODS: 331 PK studies with rich sampling were extracted from the WAPPS-Hemo database. Two sampling approaches were evaluated and compared: 974 PK studies consisting of two samples were built from the rich sampling data including one sample selected using the personalized LSA prediction; 974 PK studies consisting of two samples were built from the rich sampling data including one sample selected randomly. Half-life values were estimated on the sparse data and compared within patients to the estimates obtained on the rich data for assessing the error on half-life values. RESULTS: Relative errors between estimates from sparse sampling data using personalized LSA and from rich sampling data were always lower than 20% and significantly lower than the comparative approach that used random sampling (median-95th percentile were 3.8%-13.1% vs. 7.0%-23.5%, respectively, p-value < 10-10 ). Moreover, less than 4% of the samples suggested by the personalized LSA were below the limit of quantification. CONCLUSIONS: Identifying the most informative sampling points for PK assessment using a Personalized LSA approach that accounts for individual differences in PK improves the precision of FVIII terminal half-life estimates in sparse sampling.
引用
- Chelle P, Iorio A, Edginton AN, et al. A personalized limited sampling approach to better estimate terminal half-life of FVIII concentrates. J Thromb Haemost. 2022. PMID: 35753074. doi:10.1111/jth.15803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。